Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05025826
Other study ID # RC21_0246
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 1, 2022
Est. completion date March 2026

Study information

Verified date October 2023
Source Nantes University Hospital
Contact Yann TOUCHEFEU, Professor
Phone 02 40 08 31 63
Email yann.touchefeu@chu-nantes.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents, with a prevalence from 19% to over 85%. Clinically, CIPN is a mostly sensory neuropathy that may be accompanied by motor and autonomic changes of varying intensity and duration. Due to its high prevalence among cancer patients, CIPN constitutes a major problem for both cancer patients and survivors as well as for their health care providers, especially because, at the moment, there is no single effective method of preventing CIPN; moreover, the possibilities of treating this syndrome are very limited. The phycocyanin (PC), a biliprotein pigment and an important constituent of the blue-green alga Spirulina platensis, has been reported to possess significant antioxidant and radical-scavenging properties, offering protection against oxidative stress. Study hypothesis is that phycocyanin may give protection against oxaliplatin-induced neuropathy in the treatment of gastro intestinal cancers including oesogastric, colo-rectal and pancreatic cancers. This trial will be a randomised placebo-controlled study.


Description:

The phycocyanin used in this protocol (Phycocare®) will be 5 times more concentrated than the Spirulysat (food supplement commercialized by Algosource). It will be administrated during Oxaliplatin based chemotherapy and 3 months after oxaliplatin stopped.


Recruitment information / eligibility

Status Recruiting
Enrollment 110
Est. completion date March 2026
Est. primary completion date August 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male or female with the age > or = to 18 years old. - Negative pregnancy test for women with child-bearing potential if applicable (without hysterectomy for example) - Information given to the patient who must have signed informed consent - Patient with Histologically or cytologically proven gastro intestinal cancer including oesogastric, colo-rectal, pancreatic cancers, locally advanced pancreatic cancers and planned to be treated with oxaliplatin - Patient with metastatic disease not previously treated - Patient willing not to take any plant-based therapy during the study (including phytotherapy and gemmotherapy) - Previous radiotherapy is authorized if discontinued =15 days prior to randomization - Sites of disease evaluated within 42 days prior C1 day 1 of chemotherapy with thoracic-abdominal-pelvic CT scan (or abdominal-pelvic MRI and chest X-ray) - Patient with ECOG Performance status 0 or 1 - Patients with a Life expectancy =12 weeks - Laboratory results: Hematologic function: polynuclear neutrophils = 1.5.109/L platelets =100.109/L haemoglobin =9 g/dL Hepatic function: transaminases =2.5 times upper limit of normal (ULN) (=5 ULN in case of hepatic metastases), alkaline phosphatases =2.5 x ULN (=5 ULN in case of hepatic metastases), total bilirubin =1.5 x ULN Renal function: creatinemia clearance >50 ml/min (Cockcroft and Gault) - Patient with Public Health insurance coverage Exclusion Criteria: - Patients with phenylketonuria - Patients with known meningeal or brain metastases - Patient previously treated for their metastatic cancer - Patient previously treated with oxaliplatin - Patient with specific contraindication or known hypersensitivity to spirulina - Patient with specific contraindication or known hypersensitivity to oxaliplatin. - Known allergy or hypersensitivity to antibodies or any preservatives if patient is treated with a monoclonal antibody combined to chemotherapy (bevacizumab or cetuximab or panitumumab or nivolumab or Trastuzumab For patients treated with trastuzumab : patient without HER2 overexpression (defined by positive IHC3 or positive IHC2 and confirmed by a positive FISH result) - Patient with clinically significant coronaries affection or myocardial infarction within 6 months prior to randomization. - Patient with peripheral neuropathy >1 (CTCAE scale version 5.0). - Patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. - Patient with acute intestinal obstruction or sub-obstruction, history of inflammatory intestinal disease or extended resection of the small intestine or presence of a colic prosthesis. - Patient with unhealed wound, active oesogastric or duodenal ulcer, or bone fracture - Patient with an history of abdominal fistulas, trachea-esophageal fistulas or any other grade 4, gastro-intestinal perforations or non-gastrointestinal fistulas or intra-abdominal abscesses during the 6 months before randomization. - For patient treated with bevacizumab: patient with uncontrolled arterial hypertension (systolic pressure >150 mmHg and/or diastolic pressure >100 mmHg) with and without antihypertensive medication. Patients with high hypertension are eligible if antihypertensive medication lowers their arterial pressure to the level specified by the criterion. - Patient with an history of hypertensive crisis or hypertensive encephalopathy - Patient with other concomitant malignancy or history of cancer (except in situ carcinoma of the cervix, or non-melanoma skin cancer, treated with curative intent treatment) except if considered in complete remission for at least 2 years before randomization - Existence of any other pathology, metabolic problem, anomaly during the clinical examination or biological anomaly which may reasonable suspect an underlying pathology which would contra- indicate the use of the study medication or any other risk of complication related to the treatment. - Any treatment including an experimental drug, or participation in another clinical trial within 28 days before randomization. - Pregnant women, or women who could possibly be pregnant (or who expect to fall pregnant within 6 months of the end of treatment), or who are breast feeding are not eligible. - Men and women of child-bearing potential who do not accept to use a highly effective contraceptive (as per currently acceptable institutional standards) or abstinence during the study and for the month after the last administration of the study treatments. - Persons deprived of liberty or under guardianship. - Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

Study Design


Intervention

Other:
Phycocare
Phycocare every day during 9 months (except days of chemotherapy: no Phycocare)
Placebo
Placebo every day during 9 months (except days of chemotherapy = no Placebo)

Locations

Country Name City State
France Centre Hospitalier de Cholet Cholet
France Clermont-Ferrand UH Clermont-Ferrand
France DIJON UH Dijon
France Chd La Roche Sur Yon La Roche-sur-Yon
France Hôpital le Confluent Nantes
France Nantes Uh Nantes
France Saint Gregoire Clinique Rennes
France Mutaliste Clinic Saint Nazaire Saint-Nazaire
France Foch Suresnes Hosptial Suresnes

Sponsors (2)

Lead Sponsor Collaborator
Nantes University Hospital Algosource

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Demonstrate a 50% decrease of the grade> or = 2 neurotoxicity at 4 months after oxaliplatin-based chemotherapy start in the PHYCOCARE arm neurotoxicity according to NCI (National Cancer Institute) criteria in both arms 4 months after oxaliplatin-based chemotherapy start
Secondary Comparison between the two arms of percentage of patients who stopped oxaliplatin for neurological toxicity Delay of definitive interruption or decrease of oxaliplatin treatment last day of chemotherapy
Secondary Comparison between the two arms of percentage of patients with oxaliplatin dose decrease Dose intensity of oxaliplatin last day of chemotherapy
Secondary Comparison between the two arms of Neurological toxicities according to the Common Terminology Criteria for adverse Event (CTCAE) v5.0 Neurological AE at following hospital visit : baseline, M4 and M9/end of study visit end of study visit (an average of 9 months after cycle 1 day1)
Secondary Comparison between the two arms of Overall Toxicity (including hematological toxicity, gastro-intestinal toxicity, etc…) Adverse events grade 1 to 4 end of study visit (an average of 9 months after cycle 1 day1)
Secondary Comparison between the two arms of Patient 's Quality of Life according with EORTC-QLQ-C30 QLQ C30 - score questions 1 to 28: score frame [30-114] . 30= good quality of life questions 29 and 30 : score frame [2-14] . 2 = bad quality of lifre end of study visit (an average of 9 months after cycle 1 day1)
Secondary Comparison between the two arms of Neurological toxicities ElectroNeuroMyography (ENMG) and neurology questionnaire ONLS (overall neuropathy limitations scale)
ONLS score:
sub-score upper limbs : [0-5] . 5= worst neuropathic injury
sub score lower limbs [0-7]: 7= worst neuropathic injury
total score = upper limbs score + lower limbs score [0-12] ; 0= no injury; 12= maximal incapacity
end of study visit (an average of 9 months after cycle 1 day1)
See also
  Status Clinical Trial Phase
Recruiting NCT04618809 - Improving the Approach to and Management of the Older Patient With Metastatic Gastric Cancer N/A
Recruiting NCT02668380 - An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer N/A
Completed NCT03121807 - Home Parenteral Nutrition for Malnourished Unresectable Stage IV Gastric Cancer N/A
Recruiting NCT04358354 - Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer Phase 3
Completed NCT01099527 - A Trial of RAD001/Capecitabine in Refractory Gastric Cancer Phase 1/Phase 2
Completed NCT00253370 - Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer Phase 2
Recruiting NCT02002195 - Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer
Recruiting NCT06008925 - Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer Phase 1/Phase 2
Recruiting NCT05714124 - Liver Embolization Approaches for Tumor Management
Recruiting NCT02855788 - Metronomic Chemotherapy in Advanced Gastric Cancer Phase 2
Recruiting NCT03154983 - The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer Phase 2
Not yet recruiting NCT04263870 - Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Phase 2
Active, not recruiting NCT01359397 - Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT04739202 - Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) Phase 2
Completed NCT03409848 - Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma Phase 2
Recruiting NCT05859477 - Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer Phase 2
Recruiting NCT05955833 - 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study Phase 1
Terminated NCT01528501 - Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008) Phase 2
Completed NCT03751761 - GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study Phase 1/Phase 2
Recruiting NCT05024812 - Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Phase 1/Phase 2